PRINCETON, N.J. 鈥� The Bristol Myers Squibb-Pfizer Alliance today announced the launch of a collaboration with Mark Cuban Cost Plus 91短视频 Company (Cost Plus 91短视频s) to offer Eliquis (apixaban) on . Eliquis is one of the most widely prescribed oral anticoagulants in the United States and one of the largest brands in the space to be offered on the site, which allows patients to purchase prescription medicines directly at reduced costs, providing another avenue for patients to access the medication.
鈥淭he BMS-Pfizer Alliance is pleased to expand our direct-to-patient options for accessing Eliquis 鈥� a medicine relied upon by millions of Americans daily 鈥� to the popular Cost Plus 91短视频s platform,鈥� said , chief commercial officer, Bristol Myers Squibb. 鈥淭his new collaboration is grounded in a shared commitment to transparency and offers another meaningful solution to overcome access barriers, lower costs and broaden the availability of our medicines for the patients who need them.鈥�
Mark Cuban, co-founder, Cost Plus 91短视频s said, 鈥淲e鈥檝e heard from a lot of people asking for Eliquis on Cost Plus 91短视频s, and this is about making sure they have a clearer, more direct way to access it. People shouldn鈥檛 have to guess what they鈥檙e going to pay for a medication they depend on. When you strip away the layers that drive up costs, you give people more control over how they get their prescriptions.鈥�
Beginning April 27, 2026, Eliquis will be available on Cost Plus 91短视频s, and patients with a prescription will pay a total of $345 for a 30-day supply. Teaming up with Cost Plus 91短视频s provides another option for cash-paying patients to access Eliquis directly. This follows the 2025 launch of a direct-to-patient offering through the BMS-Pfizer Alliance鈥檚 patient resource , which is also accessible via .
Eliquis is an important treatment option for patients with atrial fibrillation (AFib), not caused by a heart valve problem, to reduce the risk of stroke and blood clots, as well as to treat blood clots in the veins of the legs (deep vein thrombosis [DVT]) or lungs (pulmonary embolism [PE]), and reduce the risk of them recurring. For every 100,000 patients treated, Eliquis has resulted in an estimated $3 billion in total healthcare cost savings and avoidance, such as hospitalization and extended rehabilitation needs.
